Gilder Gagnon Howe & CO LLC Tg Therapeutics, Inc. Transaction History
Gilder Gagnon Howe & CO LLC
- $7.02 Billion
- Q1 2025
A detailed history of Gilder Gagnon Howe & CO LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Gilder Gagnon Howe & CO LLC holds 80,777 shares of TGTX stock, worth $2.84 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
80,777
Previous 81,292
0.63%
Holding current value
$2.84 Million
Previous $2.45 Million
30.21%
% of portfolio
0.05%
Previous 0.03%
Shares
4 transactions
Others Institutions Holding TGTX
# of Institutions
415Shares Held
88.1MCall Options Held
2.34MPut Options Held
1.94M-
Vanguard Group Inc Valley Forge, PA15.6MShares$548 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$400 Million0.0% of portfolio
-
State Street Corp Boston, MA7.43MShares$261 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.28MShares$115 Million0.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.85MShares$100 Million9.29% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $5.1B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...